Revenue segments as reported by the company.

Premiums

Product revenue

Administrative fees and other revenue

Net investment income

Net gains on financial instruments

Gain on sale of business

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit expense

Selling, general and administrative

Interest expense

Amortization of other intangible assets

Loss on extinguishment of debt

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Elevance Health Inc

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elevance Health reports robust Q4 earnings, eyes margin optimization

Elevance Health's strong Q4 2022 performance, strategic acquisitions, and focus on margin optimization position the company for continued growth. With a clear outlook for 2023, emphasizing membership expansion and margin recovery, the company is poised for success. Challenges in optimizing margins and managing cost structures are balanced by growth opportunities and strategic initiatives.

Elevance Health reports robust Q1 growth and innovation in healthcare

Elevance Health Inc demonstrated strong financial performance and growth in Q1 2023, driven by increased membership and solid operating results.
The company's focus on advocacy, innovation, and sustainability, along with strategic investments in healthcare capabilities, positions it for continued success.
While facing challenges in cost management and strategic partnerships, Elevance Health is well-positioned to capitalize on opportunities in specialty care and value-based models.
Overall, Elevance Health's commitment to whole health, innovation, and value-based care sets a positive trajectory for future growth and industry leadership.

Elevance Health Inc posts robust Q2 earnings, eyes value-based care

Elevance Health Inc reported strong Q2 earnings, raised adjusted EPS outlook to over $32.85 for the year, and emphasized a focus on value-based care and digital solutions. While facing margin pressure in Carelon, the company remains confident in its strategy execution and performance for 2023 and beyond.

Elevance Health excels in Q3, eyes growth through strategic actions

Elevance Health's Q3 performance was strong, with a focus on operational efficiency and strategic investments. Challenges in Medicare ratings were addressed through proactive measures, while opportunities lie in growth acceleration and strategic partnerships. The company remains on track to achieve its long-term growth targets.

Elevance Health Inc surpasses earnings expectations, eyes growth opportunities

Elevance Health Inc's strong financial performance in Q4 2023 and full-year results, coupled with strategic initiatives in expanding capabilities and enhancing operational efficiency, position the company for continued success. Challenges in commercial repricing and Medicaid dynamics are being addressed, while opportunities in Medicare Advantage and strategic investments offer avenues for growth.

Elevance Health posts robust Q1 earnings, eyes strategic growth

Elevance Health demonstrated strong financial performance in Q1, with revenue growth and margin expansion in key segments.
While facing challenges like potential Medicare rate cuts, the company is leveraging partnerships and acquisitions for growth.
Opportunities lie in expanding service offerings, geographic footprint, and optimizing Medicaid margins for long-term sustainability.

Elevance Health Inc reports robust earnings growth and strategic wins

Elevance Health's Q2 performance reflects strong earnings growth and reaffirmed guidance, driven by solid segment performance and new business wins.
The company's strengths lie in its high Medicare rating, robust revenue growth in services, and strategic focus on value creation.
Challenges include sustaining growth momentum, managing funding cuts, and effectively integrating recent acquisitions for long-term success.
Opportunities exist in accelerating capabilities, expanding market share, optimizing operations, and leveraging workplace recognition for talent attraction and innovation.

Elevance Health faces Medicaid challenges, sees growth in AI investments

Elevance Health's Q3 earnings were impacted by elevated medical costs in Medicaid, leading to a reduction in full-year outlook. Despite challenges in the Medicaid business, the company's Medicare Advantage and Commercial businesses are performing well. Investments in AI and expansion of Carelon Services present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced the closing of its acquisition of BioPlus, a comprehensive specialty pharmacy subsidiary of CarepathRx, a portfolio company of Nautic Partners. BioPlus provides a complete range of specialty pharmacy services for patients living with complex and chronic conditions, such as cancer, multiple sclerosis, hepatitis C, autoimmune diseases, and rheumatology.

Elevance Health Announces Closing of BioPlus Acquisition

Abbott Labs

Accenture Plc

Adobe

Autodesk

Aflac

Applied Materials

Advanced Micro Devices

Amazon

Activision Blizzard

AutoZone

Broadridge Financial

Carrier Global

Caterpillar

Constellation Energy Corp

Cigna

CME Group

Copart

Cintas Corp

Deere & Company

Dollar General

Domino's Pizza

FactSet Research Systems

Fair Isaac

Three companies have been removed from my watchlist and added to the active portfolio. I added four new companies to my watchlist.

Compounders And Dividends: February 2023 Watch List Update

ELV generated outstanding revenue growth, owing to its improving medical membership growth. Despite the expected end of Medicaid's continued coverage, ELV is well-positioned to continue growing.

Elevance Health: Attractive On Its Expansion Catalysts

Centene

Humana

Molina Healthcare

UnitedHealth Group

A proposal for lower-than-expected Medicare Advantage rates in 2024 has sent shares of publicly traded health insurers falling.

Health-insurance stocks drop after Medicare Advantage proposes lower rates for 2024

This company is a leader in a massive and growing industry.

Should You Buy This Steady Dividend Growth Stock?

The giant health insurers each did well last year.

Better Buy: UnitedHealth Group or Elevance Health?

INDIANAPOLIS--( BUSINESS WIRE )--Elevance Health, Inc. (NYSE: ELV) announced today that for the six-month interest period commencing on October 15, 2022, its 2.750% Senior Convertible Debentures due 2042 (the “Debentures”) will accrue contingent interest at a rate of 0.50% per annum of the average trading price of a Debenture for the ten consecutive trading days ended October 14, 2022. Contingent interest, which the Company has determined to be approximately $16.8123 per Note, will be payable on April 15, 2023 to holders of the Debentures as of the April 1, 2023 record date.

Elevance Health's 2.750% Senior Convertible Debentures due 2042 to Accrue Contingent Interest

Elevance Health's (ELV) fourth-quarter earnings gain on solid premiums from its Medicaid business. Management approves a quarterly dividend hike of 16%.

Elevance Health (ELV) Tops on Q4 Earnings, Hikes Dividend

Elevance Health Inc. (NYSE:ELV ) Q4 2022 Earnings Conference Call January 25, 2023 8:30 AM ET Company Participants Steve Tanal - Vice President, Investor Relations Gail Boudreaux - President & Chief Executive Officer John Gallina - Chief Financial Officer Peter Haytaian - President, Carelon Morgan Kendrick - President, Commercial & Specialty Business Division Felicia Norwood - President, Government Business Division Conference Call Participants Lance Wilkes - Bernstein A.J. Rice - Credit Suisse Justin Lake - Wolfe Research Nathan Rich - Goldman Sachs Scott Fidel - Stephens Lisa Gill - JPMorgan Kevin Fischbeck - Bank of America Stephen Baxter - Wells Fargo Josh Raskin - Nephron Research Rob Cottrell - Cleveland Research Whit Mayo - SVB Securities Dave Windley - Jefferies Steven Valiquette - Barclays George Hill - Deutsche Bank Gary Taylor - Cowen Michael Ha - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Fourth Quarter Earnings Conference Call.

Elevance Health Inc. (ELV) Q4 2022 Earnings Call Transcript

Elevance Health (ELV) delivered earnings and revenue surprises of 0.58% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Elevance Health (ELV) Surpasses Q4 Earnings Estimates

INDIANAPOLIS--( BUSINESS WIRE )--Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2022 results reflecting strong financial performance, including double-digit growth in revenue, operating earnings, and adjusted earnings per share.

Elevance Health Reports Fourth Quarter and Full Year 2022 Results

OLDWICK, N.J.--( BUSINESS WIRE )--AM Best has commented that the Credit Ratings (ratings) of Elevance Health, Inc. (Elevance) (Indianapolis, IN) [NYSE: ELV] and its insurance subsidiaries entities remain unchanged following the Jan. 23, 2023, announcement that Elevance will be acquiring Louisiana Health Service and Indemnity Company dba Blue Cross and Blue Shield of Louisiana (BCBSLA). BCBSLA is an independent licensee of the Blue Cross Blue Shield Association and offers a diversified portfolio of health products that are similar to the core insurance subsidiaries of Elevance. BCBSLA serves more than 1.9 million members with approximately $1.8 billion in capital and surplus as of year-end 2021.

AM Best Comments on Credit Ratings of Elevance Health, Inc. and Its Subsidiaries Following Acquisition Announcement

Terms of the deal weren't disclosed. Blue Cross and Blue Shield of Louisiana has about 1.9 million members.

Elevance to Acquire Louisiana Nonprofit Health Insurer

INDIANAPOLIS--( BUSINESS WIRE )--Elevance Health, Inc. (NYSE: ELV) and Blue Cross and Blue Shield of Louisiana announced today that the companies have entered into a definitive agreement through which Elevance Health agrees to acquire Blue Cross and Blue Shield of Louisiana (BCBSLA). BCBSLA will join Elevance Health's affiliated Anthem Blue Cross Blue Shield family of brands.

Elevance Health to Acquire Blue Cross and Blue Shield of Louisiana

Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.

Elevance Health (ELV) to Post Q4 Earnings: What to Expect

Sanofi

It's difficult to imagine a future where healthcare isn't in high demand.

Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023

Elevance Health Inc. is a massive company operating in the insurance space, with over 47 million members. Elevance Health revenues continue to climb and the company is able to pass down some expenses.

Elevance Health Offers Great Value

Shares of several health insurers rallied in trading on Friday after UnitedHealth Group Inc. UNH, +1.79% reported better-than-expected profit and revenue in the fourth quarter of 2022. Elevance Health Inc.'s ELV, +2.52% stock was up 2.6%, while shares of Cigna Corp. CI, +2.24% gained 2.2%, and shares of CVS Health Corp. CVS, +1.21% , which owns Aetna, were up 1.1%.

Elevance Health, Cigna's stocks gain

INDIANAPOLIS--( BUSINESS WIRE )--Elevance Health (NYSE: ELV) will release fourth quarter 2022 financial results on January 25, 2023, at 6:00 a.m. Eastern Standard Time (“EST”). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter Results on January 25, 2023

Elevance Health (ELV) remains well-poised for growth due to a growing customer base within its Government and IngenioRx businesses coupled with solid cash-generating abilities.

Why You Should Hold Elevance Health (ELV) in Your Portfolio

The Health Care sector is favored by many analysts in 2023 for its somewhat insulated profit growth. One large-cap in the managed health care industry sports double-digit EPS growth in the years ahead.

Elevance Health: Strong And Steady EPS Growth Ahead, High Relative Strength Name

Bank of America

British American Tobacco

Alphabet

JPMorgan Chase & Co

Robert Half Int.

Starbucks

Tyson Foods

Texas Instruments

Union Pacific

Visa

No matter your investor profile, sector needs, or approach, there should be something of interest to be found here. I highlight ten companies for the dividend investor across many different sectors with both high and low initial yields while painted in the picture of my 2023 outlook.

My Top 10 Dividend Companies To Watch Out For In 2023

Progyny

ELV vs. PGNY: Which Stock Is the Better Value Option?

Health care has been a nightmare of a place to invest in over the last year. One area of the health care space that has withstood the sharp declines, however, are those companies that operate in the managed plans area of the sector.

Elevance: A Standout Health Care Stock

T-Mobile US

Viking Global Investors LP, the firm founded by Andreas Halvorsen (Trades, Portfolio), disclosed in a regulatory filing that its top five trades during the third quarter included the closure of its position in Centene Corp. ( CNC , Financial) and American International Group Inc. ( AIG , Financial), a reduction to its holding of T-Mobile US Inc. ( TMUS , Financial) and boosts to its investments in Visa Inc. ( V , Financial) and Elevance Health Inc. ( ELV , Financial).

News for Elevance Health Inc Stock (ELV)